- Home
- DNTH vs BLMN Comparison
DNTH vs BLMN Comparison
Compare DNTH & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- BLMN
- Stock Information
- Founded
- DNTH 2015
- BLMN 1988
- Country
- DNTH United States
- BLMN United States
- Employees
- DNTH N/A
- BLMN N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- BLMN Restaurants
- Sector
- DNTH Health Care
- BLMN Consumer Discretionary
- Exchange
- DNTH Nasdaq
- BLMN Nasdaq
- Market Cap
- DNTH 657.0M
- BLMN 714.5M
- IPO Year
- DNTH N/A
- BLMN 2012
- Fundamental
- Price
- DNTH $17.39
- BLMN $7.63
- Analyst Decision
- DNTH Strong Buy
- BLMN Hold
- Analyst Count
- DNTH 8
- BLMN 11
- Target Price
- DNTH $53.00
- BLMN $13.75
- AVG Volume (30 Days)
- DNTH 255.5K
- BLMN 2.9M
- Earning Date
- DNTH 05-12-2025
- BLMN 05-07-2025
- Dividend Yield
- DNTH N/A
- BLMN 7.86%
- EPS Growth
- DNTH N/A
- BLMN N/A
- EPS
- DNTH N/A
- BLMN N/A
- Revenue
- DNTH $6,524,000.00
- BLMN $3,930,996,000.00
- Revenue This Year
- DNTH N/A
- BLMN $1.28
- Revenue Next Year
- DNTH N/A
- BLMN $1.67
- P/E Ratio
- DNTH N/A
- BLMN $8.44
- Revenue Growth
- DNTH 102.36
- BLMN N/A
- 52 Week Low
- DNTH $13.37
- BLMN $6.09
- 52 Week High
- DNTH $32.27
- BLMN $22.34
- Technical
- Relative Strength Index (RSI)
- DNTH 35.86
- BLMN 45.27
- Support Level
- DNTH $17.40
- BLMN $7.62
- Resistance Level
- DNTH $18.45
- BLMN $8.03
- Average True Range (ATR)
- DNTH 1.21
- BLMN 0.43
- MACD
- DNTH -0.22
- BLMN -0.07
- Stochastic Oscillator
- DNTH 10.60
- BLMN 14.37
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About BLMN Bloomin' Brands Inc.
Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.